Want to see TSE:TMED.X full AI Analyst Report?
Top Page
EGF Theramed Health
(TMED.X)
Select Model
Select Model
Rating:38Underperform
Price Target:
C$0.08
▲(7.14% Upside)
Action:Reiterated
Date:12/30/25
The score is driven down primarily by very weak financial performance (no revenue, ongoing losses, negative equity and a thin asset base), compounded by strongly bearish technical momentum (below key moving averages with negative MACD and extremely low RSI). Valuation offers limited support because earnings are negative and no dividend yield is available.
Positive Factors
Improving Cash Generation
The shift to slightly positive operating and free cash flow in 2025 signals emerging cash generation after several years of negative flows. Although the amount is small, sustained positive cash flow would reduce near-term financing needs and provide a foundation for incremental investment or product commercialization.
Negative Factors
No Reported Revenue
Zero reported revenue across the available periods shows the company lacks commercialized products or monetization. Without recurring revenue, long-term viability depends on successful product launches or continual external funding, substantially increasing execution and dilution risk for stakeholders.
Read all positive and negative factors
Positive Factors
Negative Factors
Improving Cash Generation
The shift to slightly positive operating and free cash flow in 2025 signals emerging cash generation after several years of negative flows. Although the amount is small, sustained positive cash flow would reduce near-term financing needs and provide a foundation for incremental investment or product commercialization.
Read all positive factors
EGF Theramed Health (TMED.X) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$638.92K
Dividend YieldN/A
Average Volume (3M)33.00
Price to Earnings (P/E)―
Beta (1Y)0.04
Revenue GrowthN/A
EPS Growth-658.87%
CountryCA
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-0.26
Shares Outstanding11,616,665
10 Day Avg. Volume0
30 Day Avg. Volume33
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.26
Price to Sales (P/S)0.00
P/FCF Ratio38.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
EGF Theramed Health Business Overview & Revenue Model
Company Description
EGF Theramed Health Corp. focuses on providing psychedelic-based therapies to address various mental health challenges. The company's products are specifically utilized in the treatment of conditions such as intractable depression, anxiety disorde...
How the Company Makes Money
null...
EGF Theramed Health Financial Statement Overview
Summary
Income Statement
6
Very Negative
Balance Sheet
4
Very Negative
Cash Flow
18
Very Negative
| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ― |
| EBITDA | -2.21M | -2.33M | -238.64K | -568.50K | -1.35M | -677.89K |
| Net Income | -3.09M | -3.21M | -269.25K | -623.00K | -1.69M | -968.71K |
Balance Sheet | ||||||
| Total Assets | 18.25K | 22.34K | 214.41K | 193.69K | 178.67K | 1.20M |
| Cash, Cash Equivalents and Short-Term Investments | 10.47K | 14.01K | 10.01K | 11.72K | 15.23K | 702.63K |
| Total Debt | 1.63M | 1.51M | 1.47M | 1.34M | 1.22M | 1.12M |
| Total Liabilities | 6.06M | 5.93M | 2.92M | 2.67M | 2.51M | 2.41M |
| Stockholders Equity | -4.64M | -4.52M | -1.34M | -1.14M | -1.02M | 91.48K |
Cash Flow | ||||||
| Free Cash Flow | 82.28K | 29.75K | -134.71K | -576.01K | -993.42K | -783.76K |
| Operating Cash Flow | 82.30K | 29.75K | -134.71K | -576.01K | -993.42K | -783.76K |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 410.43K |
| Financing Cash Flow | 104.98K | -25.75K | 133.00K | 572.50K | 306.02K | 712.20K |
EGF Theramed Health Technical Analysis
Negative
0.07
Price Trends
0.07
Negative
0.07
Negative
0.07
Negative
Market Momentum
>-0.01
Negative
0.08
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:TMED.X, the sentiment is Negative. The current price of 0.07 is above the 20-day moving average (MA) of 0.06, above the 50-day MA of 0.07, and below the 200-day MA of 0.07, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 0.08 is Positive, neither overbought nor oversold. The STOCH value of 0.00 is undefined, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:TMED.X.
EGF Theramed Health Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | C$6.58M | -3.23 | 739.84% | ― | ― | -28.35% | |
45 Neutral | C$2.89M | -16.67 | -49.83% | ― | -100.00% | 42.39% | |
38 Underperform | C$638.92K | -0.38 | 66.83% | ― | ― | -658.87% | |
38 Underperform | C$3.31M | -19.19 | 8.34% | ― | ― | 98.15% | |
38 Underperform | C$4.64M | -1.21 | 184.91% | ― | ― | 43.30% |
* Healthcare Sector Average
TSE:TMED.X
EGF Theramed Health
0.06
-0.05
-45.00%
TSE:NDAT
nDatalyze Corp
0.07
0.06
366.67%
TSE:KETA
TripSitter Clinic Ltd
0.19
0.09
90.00%
TSE:NARA
PanGenomic Health, Inc. Class A
0.25
-2.00
-88.89%
TSE:DMED
DiagnaMed Holdings Corp.
0.05
-0.03
-37.50%
EGF Theramed Health Corporate Events
Business Operations and StrategyExecutive/Board Changes
EGF Theramed refreshes board and finance leadership
Positive
Mar 4, 2026
EGF Theramed Health Corp. has appointed Lin Ye to its board of directors and named Connor Yuen as interim chief financial officer, following the resignation of former CFO and director Usama Chaudhry. The changes bring leadership with experience in...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.